C5

C5's 18th Annual Forum on

PHARMA & BIOTECH PATENT LITIGATION IN EUROPE

21 – 22 May 2025
Radisson BLU Hotel, Amsterdam City Center
Amsterdam

2025 Conference Co-Chairs:

Liz Cohen
Partner
Bristows LLP

Dr. Kai Rüting
Partner
Vossius & Partner

Ruud van der Velden
Partner
Hogan Lovells

UPC Judges:

Hon. Peter Blok
Presiding Judge
Unified Patent Court, Court of Appeal, Luxembourg

Mr. Edger F. Brinkman
Judge
Unified Patent Court, the Hague

Attend to Gain Insights, Global Perspectives and Develop Winning Strategies. Our Stellar Faculty will Help You:

- **ANALYZE** the emerging litigation trends in the UPC and national courts
- **ENGAGE** with Judges from the UPC
- **DEMYSTIFY** forum selection and parallel proceedings
- **NAVIGATE** the evolving EU regulatory landscape and its impact on IP
- **ADAPT** to EU competition law enforcement trends and cadence
- **FINE-TUNE** your SPC strategies

Association and In-House Insights From:

- Adalvo
- AstraZeneca
- EFPIA
- Farmaprojects S.A.U.
- Fresenius Kabi
- Medicines for Europe
- Merck Sharp & Dohme
- Sanofi
- VIZGEN

REGISTER NOW C5-Online.com/**PPLitigation** • +44 20 4532 2313

Part of C5 Group's
LIFE SCIENCES GLOBAL SERIES

After a transformative first year, the body of case law from the UPC continues to expand—bringing clarity in some areas while introducing uncertainty in others, particularly where national and international laws conflict or diverge. Coupled with ongoing regulatory reforms, these developments place life sciences IP lawyers at a critical juncture, requiring a keen understanding of the far-reaching implications and emerging challenge.

C5's 18th Annual Forum on Pharma & Biotech Patent Litigation in Europe stands as a pivotal assembly for legal professionals and life sciences executives navigating the ever-evolving terrain of pharmaceutical and biotechnological patent law. In a year marked by significant legal shifts and regulatory transformations, this forum is designed to dissect, understand, and forecast the implications of these changes on the industry. From the developing case law and operational nuances of the Unified Patent Court (UPC) to the intricacies of international patent litigation and the latest in EU regulatory reforms, the forum promises a comprehensive exploration of the current patent litigation landscape.

The forum also serves as a prime networking opportunity, bringing together the elite of the European life sciences patent bar to exchange ideas, share experiences, and forge connections that will drive the future of the field. **Whether you're a litigator defending the interests of a pharma/biotech company, or in-house counsel navigating the patent challenges of a global pharma corporation, this event is poised to offer valuable perspectives and actionable insights**.

Join us at C5's 18th Annual Forum to engage with the forefront of legal and regulatory developments in pharma and biotech patent litigation. **Together, we will explore the latest challenges and opportunities, shaping the strategies that will define the future of the industry.**

Liz Cohen, Partner, Bristows LLP

I'm very much looking forward to Co-chairing and Speaking a this year's C5 Pharma & Biotech Patent Litigation Forum in Amsterdam. With an interesting agenda covering a number of thought provoking topics, together with a wide variety of expert speakers, it promises to be another engaging and excellent event.

Dr. Kai Rüting, Partner, Vossius & Partner

The C5 Pharma & Biotech Patent Litigation conference is always a great forum to get the most recent updates and trends on cross-border life sciences litigation. I think this year's event will be exceptional because we will discuss and analyze the first pharma and biotech decisions of the Unified Patent Court with in-house counsel, litigators and judges. I look forward exchanging experiences and ideas in these dynamic times as well as engaging in discussions on key developments and strategies.

Ruud van der Velden, Partner, Hogan Lovells

The upcoming C5 Pharma & Biotech Patent Litigation conference in Amsterdam promises to be a great event, with insights from in-house counsel, litigators and judges on various hot topics, including developments in the national courts, the EPO and the UPC, as well as regulation reforms and public policy. I'm very much looking forward to co-chairing the event, seeing many familiar and new faces and having some interesting debates!

Complimentary Webinar

Preliminary Forum Selection Insights & Strategies

16 APRIL 2025 • 13H00–14H00 CET

Hosted by

Liz Cohen
Partner, **Bristows LLP**

Dr. Kai Rüting
Partner, **Vossius & Partner**

Gertjan Kuipers
Partner, **Hogan Lovells**

LEARN MORE

Learn and Connect with C5's Life Sciences IP Portfolio Advisory Board

C5's Global Life Sciences IP Advisory board was created as a part of C5's ongoing effort to provide industry leading content and a world renowned speaker faculty. The board is composed of a selection of advisers from around the globe, including leading pharmaceutical and biotech companies. This 'inner circle' counsels C5 on the impact of litigation trends and emerging topics.

Advisory Board

Heidi Adler
Director,
Intellectual Property Rights
Orion Corporation

Brigitte Carion-Taravella
Principal Patent Counsel,
Lead Biologics IP EU
Global IP Department, Legal,
Ethics & Business Integrity
Sanofi

Monika Dorda
SVP & General Counsel
Global Pharmaceuticals
GSK

Dr. Sabrina Duschner
VP Patent Litigation Strategy
Fresenius Kabi Deutschland GmbH

Julia Pike
Global IP Head
Sandoz

Guido Pontremoli, Ph.D.
Global IP Head, Corp.
Intellectual Property – Patents
Chiesi Farmaceutici S.p.A.

Karin Pramberger
Head of IP
Polpharma Group

Laura Reynolds
Associate General Counsel
European IP and Regulatory Litigation
Teva Pharmaceuticals

Jiri Slavik
Director, IP
Adalvo

Shohta Ueno
Senior Director
Assistant General Counsel – Dispute Resolution
Regeneron

Emeritus Members

Dominic Adair
Partner
Bristows LLP (U.K)

Bert Oosting
Partner
Hogan Lovells

REGISTER NOW C5-Online.com/**PPLitigation** • +44 20 4532 2313

Part of C5 Group's
LIFE SCIENCES GLOBAL SERIES

Distinguished Speakers

2025 CONFERENCE CO-CHAIRS

Liz Cohen
Partner
Bristows LLP

Dr. Kai Rüting
Partner
Vossius & Partner

Ruud van der Velden
Partner
Hogan Lovells

UPC JUDGES

Mr. Edger F. Brinkman
Legally Qualified Judge, Local Division, The Hague
Unified Patent Court

Hon. Peter Blok
Presiding Judge
Unified Patent Court, Court of Appeal, Luxembourg

GOVERNMENT

Boris Andrejaš
Case Handler Officer
European Commission, DG Competition

Dolores Cassidy
Head of SPC and Patent Examination
Intellectual Property Office of Ireland

Dr. Martijn de Lange
Patent Examiner
Netherlands Patent Office

Elodie Ferraty
Head of Chemistry Division
National Industrial Property Institute (INPI)

Dr. Sönke Holtorf
Director, Biotechnology
European Patent Office

ACADEMICS

Adam Mossoff
Professor of Law
Antonin Scalia Law School, George Mason University

Professor Willem Hoyng
Partner
Hoyng Rokh Monegier
Chairman
Advisory Committee of the UPC
Member
Drafting Committee of the Rules of Proceedings of the UPC

ASSOCIATIONS

Sergio Napolitano
General Counsel and External Relations Director
Medicines for Europe

Michael Swita
Director of IP Policy
European Federation of Pharmaceutical Industries and Associations (EFPIA)

IN-HOUSE COUNSEL

Sabrina Duschner
Vice-President, Patent Litigation
Fresenius Kabi

James Horgan
Chief IP Counsel, International Litigation and Policy
Merck Sharp & Dohme (UK)



Dr Rose Hughes
Patent Attorney & IP Strategist
Evolve

Dámaso Gallardo
European Patent Attorney and Litigator
Farmaprojects S.A.U.

Simona Levi, Ph.D.
Chief Legal Officer
VIZGEN



Mark Ness
Assistant General Counsel, IP
AstraZeneca

Richie Paul, Ph.D.
VP & Head of IP
Alkermes Pharma Ireland Limited

Kristof Roox
Partner
Crowell Moring LLP

Jiri Slavik
Director of IP
Adalvo

Brigitte Taravella-Carion, Ph.D.
European Patent Attorney
Sanofi

LAW FIRMS

Nina Bayerl
Partner
Freshields

Christopher Brückner
Partner
Denemeyer Law

David Carling, PhD
Partner | UK & European Patent Attorney | UPC Representative
Potter Clarkson

Emma Demetriades
Partner
Carpmaels & Ransford LLP

Catherine Drew
Partner
Pinsent Masons

Dr. Eva Ehlich
Partner
Maiwald Intellectual Property

Mike Gruber, LL.M.
Partner | UPC Representative
HOFFMANN EITLE

Eduardo Hallak
Founding Partner
Licks Attorneys

Christian Helbig
Founding Partner | Patent Attorney
WAGNER + HELBIG IP Counselors Switzerland

Dr. Ian Jones
European & UK Patent Attorney | UPC Representative
Gill Jennings & Every LLP

Oliver Kingsbury
Partner
Elkington & Fife LLP

Oscar Lamme
Partner | UPC Representative
Simmons & Simmons Netherlands

Markus Rieck
Partner
Fuchs Patentanwälte Partnerschaft mbB

Daniel G. Rudoy, PhD
Shareholder | Executive Committee Member
Wolf, Greenfield & Sacks, P.C.

Dr. Moritz Schroeder
Counsel
Bird & Bird

Camille Terfve
Partner
Mewburn Ellis

Pamela Tuxworth
Partner | European & UK Patent Attorney
J A Kemp

Ingrid Vandenborre
Co-head European Antitrust/ Competition Practice
Skadden, Arps, Slate, Meagher & Flom LLP

Anita Varma
Partner
White & Case LLP

Huiya Wu
Partner
Goodwin Procter LLP

Dr. Tobias Wuttke
Equity Partner
BARDEHLE PAGENBERG

Dr. Jörk Zwicker
Partner
Zwicker Schnappauf & Partner

21 May | Day One

> *Good networking opportunities with in-house Counsel and leading IP law firms. Hot topics, great speakers and convenient number of attendants.*
>
> **Anna Lopez Lozano, ESTEVE QUÍMICA**

7h45 Registration and Breakfast

8h45 Opening Remarks and Year in Review from the Conference Co-Chairs

Liz Cohen
Partner
Bristows LLP

Dr. Kai Rüting
Partner
Vossius & Partner

Ruud van der Velden
Partner
Hogan Lovells

C5'S UPC INSTITUTE

9h15 Plausibility and Post-Publication Evidence in Inventive Step: Emerging Trends Since G2/21

- Analyzing the guiding principles set by the Enlarged Board for using post-published evidence in inventive step assessment in the G2/21 decision and subsequent written decision of T0116/18 (the referring case which led to the G2/21 decision)
- Differentiating between the EPO approach and that used by the UPC
- Reconciling the EPO's application with national courts and navigating inconsistent applications
  - » E.g., Dutch court of appeal issued two recent decisions on plausibility, but these are not applied at the EPO
- Detailing the impact of these decisions on determining inventive step and devising strategies for effectively incorporating post-published evidence in light of national, UPC and EPO decisions

Dr. Sönke Holtorf
Director, Biotechnology
European Patent Office

Dr. Eva Ehlich
Partner
Maiwald Intellectual Property

MODERATED BY:
Dr. Ian Jones
European & UK Patent Attorney | UPC Representative
Gill Jennings & Every LLP

10h15 Navigating Preliminary Injunctions at the UPC: Key Developments and National Comparisons

- Analyzing the developing caselaw for preliminary injunctions at the UPC
- Establishing "sufficient certainty" that the patent in suit is valid and infringed
- Interpreting the standard of "urgency" throughout the Local Divisions
  - » E.g., "imminent infringement" (in the biosimilar preliminary injunction case between Novartis and Celltrion)
  - » E.g., "unreasonable delay" (UPC Court of Appeal in Ortovox v Mammut)
- Navigating the presumptions with respect to irreparable harm
- Identifying the prerequisites for re-opening a UPC preliminary injunction case
  - » E.g., in the diagnostic device case between NanoString and 10x Genomics

Simona Levi, Ph.D.
Chief Legal Officer
VIZGEN

Dr. Tobias Wuttke
Equity Partner
BARDEHLE PAGENBERG

Dr. Moritz Schroeder
Partner
Bird & Bird

MODERATED BY:
Anita Varma
Partner
White & Case LLP

11h00 Networking Break

Global Sponsorship Opportunities

With conferences in the United States, Canada, Latin America and Europe, the C5 Group of Companies: American Conference Institute, Canadian Institute, and C5 Group, provides a diverse portfolio of conferences, events and roundtables devoted to providing business intelligence to senior decision makers responding to challenges around the world.

Don't miss the opportunity to maximise participation or showcase your organisation's services and talent. For more information please contact us at: SponsorInfo@C5-Online.com

11h15 UPC Judge's Panel: Insights from the Bench

Hon. Peter Blok
Presiding Judge
Unified Patent Court, Court of Appeal, the Hague

Mr. Edger F. Brinkman
Legally Qualified Judge, Local Division, The Hague
Unified Patent Court

INTERVIEWED BY:
Professor Willem Hoyng
Partner, **Hoyng Rokh Monegier**
Chairman, **Advisory Committee of the UPC**
Member, **Drafting Committee of the Rules of Proceedings of the UPC**

In this special fireside chat, attendees will benefit from a firsthand judicial accounting of how the UPC has influenced patent litigation in Europe, including changes in procedural dynamics, case management, and decision-making trends.

12h00 G1/24 Referral on Claim Interpretation When Assessing Patentability: Resolving Disharmony in EPO and UPC Case Law?

The EPO Enlarged Board of Appeal has heard oral arguments on a critical question: whether or not, and to what extent, the claims of a European patent can be interpreted using the description and figures. Settling the disharmony of EPO case law, and harmonizing the EPO and UPC's approach, will provide important guidance on how to interpret the validity of the patent and the scope of protection provided by the patent. Topics of discussion include:

- Identifying the key cases that led to the divergence in EPO case law with reference to Articles 69 and 84 EPC
  - » E.g., the approach used in T 0169/20, T 0223/05, T 1924/20 versus the approach used in T 556/02, T 1473/19, and the ongoing proceedings in T 439/22 (where the Board referred the claim interpretation questions to the Enlarged Board of Appeal)
- Identifying the UPC's approach to claim interpretation at first instance and at the Court of Appeal
  - » E.g., the first instance infringement action filed by 10x Genomics against NanoString; NanoString's subsequent appeal (CoA decision UPC_CoA_335/2023); and NanoString's parallel EPO opposition proceedings
- Analyzing the submissions of the amicus curiae briefs and the letter from the president of the EPO for the referral
- Summarizing the oral arguments in the referral (scheduled to be heard March 2025)
- Forecasting the Enlarged Board's decision and adjusting patentability strategies accordingly

Sabrina Duschner
Vice-President, Patent Litigation
Fresenius Kabi

Dr Rose Hughes
Patent Attorney & IP Strategist
Evolve

Emma Demetriades
Partner
Carpmaels & Ransford LLP

MODERATED BY:
Markus Rieck
Partner
Fuchs Patentanwälte Partnerschaft mbB

12h45 Networking Luncheon

13h45 Advancements in Antibody Patent Prosecution: Distilling Strategies for Future Success from the UPC, EU and US Case Law

Session leaders will dissect recent influential decisions and explore their implications for prosecution and litigating antibody patents in different jurisdictions. Topics of discussion will include:

- Adopting effective strategies for claiming antibodies, considering different patent office interpretations and how to draft claims that secure protection across jurisdictions
- Examining how recent EPO decisions, like T 0499/18, and the UPC Central Division's revocation of Amgen's patent, influence the acceptability of claims where a combination of antigen plus function is used to define an antibody
- Contrasting the U.S. Supreme Court's decision, which deemed claims of two Amgen patents invalid due to insufficient enablement for a genus of antibodies, with UPC caselaw
- Understanding the nuances of epitope-based claims, functional antibody claims, combination therapies, companion diagnostics

Pamela Tuxworth
Partner | European & UK Patent Attorney
J A Kemp

Dr. Jörk Zwicker
Partner
Zwicker Schnappauf & Partner

MODERATED BY:
Ruud van der Velden
Partner
Hogan Lovells
2025 Co-Chair

14h30 Demystifying Forum Selection and Parallel Proceedings: Developing Strategic Litigation Pathways at the UPC and Beyond

- Deciphering which substantive law applies at the UPC
  - » E.g., what are the tendencies of the UPC's Local Divisions in applying EPO and national law?
- Distilling the factors for selecting the Local Division versus other venue
- Analyzing the role and use of experts in infringement and invalidity proceedings at the UPC
- Analyzing the evolving relationship between EPO opposition proceedings and validity challenges within the UPC
- Assessing how decisions in one forum influence strategies and outcomes in the other and navigating parallel proceedings
- Assessing if the UPC is a pharma-friendly venue through an analysis of the first decisions
- Contrasting the UPC with the U.S., the UK, the Netherlands and Germany

Liz Cohen
Partner
Bristows LLP
2025 Co-Chair

Oscar Lamme
Partner | UPC Representative
Simmons & Simmons Netherlands

MODERATED BY:
Dr. Kai Rüting
Partner
Vossius & Partner
2025 Co-Chair

15h30 Networking Break

15h45 Updated Strategies for Defending and Enforcing Patent Rights in Non-UPC Jurisdictions: Spotlight on Brazil and China

- Analyzing the impact of UPC developments on non-member states and how these jurisdictions are responding to the changing European patent landscape
- Exploring the specific challenges and opportunities in Brazil and China, highlighting their unique patent environment and implications for global patent strategies
- Identifying the key considerations for enforcing patents in non-UPC jurisdictions
- Developing defense strategies and tactics for patent litigation in these jurisdictions

Eduardo Hallak
Founding Partner
Licks Attorneys

Huiya Wu
Partner
Goodwin Procter LLP

16h45 Developments in EU Competition Law Affecting Pharmaceutical Patents: Preparing for New Enforcement Trends and Economic Impacts

In January 2024, the EC published a report providing an overview of the enforcement of EU antitrust and merger rules between 2018 and 2022. Then in October 2024, the EC fined Teva 462.6 million euros for allegedly abusing its dominant position to delay competition to its blockbuster multiple sclerosis pharmaceutical, Copaxone. The radical ruling, which Teva is appealing, and the EC's enforcement report, provide valuable insights into the enforcement cadence of Europe's antitrust authorities and raises important questions as to the boundary between legitimate and illegal means of competition in the pharmaceutical sector.

Boris Andrejaš
Case Handler Officer
European Commission, DG Competition

Ingrid Vandenborre
Co-head European Antitrust/ Competition Practice
Skadden, Arps, Slate, Meagher & Flom LLP

MODERATED BY:
Brigitte Taravella-Carion, Ph.D.
European Patent Attorney
Sanofi

- Reviewing the core principles and past cases that have interpreted "abuse of dominant position" under Article 102 of the Treaty on the Functioning of European Union and "misuse" of the patent system
  - » E.g., the January 2024 report published by the EC
- Analyzing the facts of the Teva case and identifying the two practices the EC considered as delaying competition
- Unpacking the EC's finding that Teva "artificially" extended its patent protection for Copaxone through playing "the divisionals game"
- Dissecting the EC's finding that Teva engaged in exclusionary disparagement of a competing glatiramer acetate
- Creating a roadmap for the future of divisional applications that incorporates this unprecedented enforcement cadence
- Developing defensive strategies against large patent portfolios
- Contacting the EC to potentially launch an investigation

17h30 Networking Cocktail

18h30 Conference Adjourns to Day Two

22 MAY | DAY TWO

Important subject matters to discuss presented by renowned specialists. An important conference to attend.

Manuel Duraes Rocha, ABREU ADVOGADOS

8h00 Registration and Breakfast

8h50 Co-Chairs' Welcome Back and Recap of Day One

Liz Cohen
Partner
Bristows LLP

Dr. Kai Rüting
Partner
Vossius & Partner

Ruud van der Velden
Partner
Hogan Lovells

9h00 Changes to IP Regulatory Rights Flowing from the EU Pharmaceutical Law and Regulation Reforms: Key Takeaways for Industry

The proposed legislation includes several regulatory updates that are critical to the work of litigators and patent attorneys as they directly impact life cycle management of valuable biopharma patents. The following changes from the proposed legislation and regulation will be highlighted, and their impact on life cycle management explored:

Orphan Market Exclusivity (OME)

- Unpacking the Commission's new concept of modulated OME with varying exclusivity periods depending on the type of orphan product
- Appreciating the impact of the Commission's proposed global orphan marketing authorization

Regulatory Data Protection (RDP)

- Appreciating the changes needed to account for a shortened regulatory and market exclusivity protection (the Commission's proposed two-year reduction in baseline RDP
- Utilizing the potential extensions of RDP, currently listed as cumulative and with no cap

New Transparency Laws

- Rethinking market applications in light of new transparency laws that require much earlier disclosure of clinical trial results

Bolar Exemption

- Anticipating the impact expanded scope of the Bolar exemption on patent and litigation strategies

Sergio Napolitano
General Counsel and External Relations Director
Medicines for Europe

Michael Swita
Director of IP Policy
European Federation of Pharmaceutical Industries and Associations (EFPIA)

MODERATED BY:
Mike Gruber, LL.M.
Partner | UPC Representative
HOFFMANN EITLE

C5'S SPC THINK TANK

10h00 The Unitary SPC and the Recast of Existing SPC Regulation: Developing Strategies for the New EU SPC Landscape

- Understanding how the proposed unitary SPC integrate with the unitary patent system
  - » Appreciating the expected benefits and challenges of a centralized SPC application procedure
- Analyzing the Impact on filing strategies and implementation
  - » How will the new unitary SPC system affect current SPC filing strategies under the Unified Patent Court?
  - » What are the key considerations for implementing a unitary SPC, and which institution might be best suited for this role?
- Debating the coexistence of unitary and national SPCs
  - » How should the industry navigate the coexistence of unitary and national SPCs?
  - » What could be the implications of a unified examination and grant procedure for both types of SPCs?
- Addressing legal uncertainties and solutions
  - » What potential legal uncertainties could arise from the new SPC reforms?
  - » What are the practical challenges in implementing the unitary SPC, especially regarding examination, granting, and appeals?
  - » How can these uncertainties be addressed to ensure a smooth transition and effective implementation?

Dr. Martijn de Lange
Patent Examiner
Netherlands Patent Office

Jiri Slavik
Director of IP
Adalvo

David Carling, PhD
Partner | UK & European Patent Attorney | UPC Representative
Potter Clarkson

MODERATED BY:
Christopher Brückner
Partner
Denemeyer Law

11h00 Morning Networking Break

11h15 The Key Cases to Consider for Your SPC Strategy: From Active Ingredient to Combination Products and Beyond

- Navigating Combination Products:
  - » Advocate General joint cases *Teva II C-119/22* and *MSD C-149/22*
- Analyzing "loose" combinations
  - » UK Court of Appeal *Newron Pharmaceuticals v The Comptroller General of Patents* ([2024] EWCA Civ 128)
- Benchmarking the status of Forsgren applications
  - » France's Supreme Court decision to uphold the rejection of the Herceptin Hylecta SPC Application (Court de Cassation appeal number 21-15.221) and the UK IPO's rejection of the Herceptin Hylecta and Mabthera SPC applications (IPO decision BL O/0257/24)
- Exploring the CJEU's interpretation of Article 3(b) and 3(d) of the SPC Regulation
  - » CJEU Genmab C-181/24
- Strategizing new medical indications and second medical use:
  - » Merck Serono's appeal to the Court of Appeal of England and Wales, attempting to overturn *Santen*
- Scrutinizing antibody SPC applications, article 3(a) post-*Royalty Pharma* (C-650/17)
  - » The French Supreme Court's pending decision on Dana-Farber's SPC application for avelumab and correlated applications (e.g., the Portuguese Supreme Court's decision to reject Dana-Farber's application for atezolizumab)

Dolores Cassidy
Head of SPC and Patent Examination
Intellectual Property Office of Ireland

Christian Helbig
Founding Partner | Patent Attorney
WAGNER + HELBIG IP Counselors Switzerland

Elodie Ferraty
Head of Chemistry Division
National Industrial Property Institute (INPI)

MODERATED BY:
Oliver Kingsbury
Partner
Elkington & Fife LLP

Mark Ness
Assistant General Counsel, IP
AstraZeneca

12h15 Networking Luncheon

13h30 The Generic and Biosimilar Landscape: SPC Manufacturing Waiver, Market Trends and Emerging Litigation Strategies

- Analyzing the impact of the SPC Manufacturing Waiver on the generic and biosimilar industries
  - » Identifying the emerging litigation trends arising from the waiver's use
  - » Distilling insights from the SPC manufacturing waiver review
- Comparing data requirements for the approval of a biosimilar versus the reference medicine in the EU
- Assessing the impact of different EU Member States decision regarding the automatic substitution of biosimilars at the pharmacy level on market uptake
- Comparing EU biosimilar uptake in cancer, diabetes, and rheumatoid arthritis
- Navigating the generic and biosimilar markets amid challenging US litigation trends
  - » Analyzing when and whether to engage the in the patent dance

Jiri Slavik
Director of IP
Adalvo

Catherine Drew
Partner
Pinsent Masons

Dámaso Gallardo
European Patent Attorney and Litigator
Farmaprojects S.A.U.

MODERATED BY:
Kristof Roox
Partner
Crowell Moring LLP

14h15 Networking Break

15h00 Patents, Public Health, and Pandemic: Navigating Litigation and Licensing While Balancing Access and Innovation

This session will analyze the COVID-19 vaccine litigations as part of the debate on the intersection of patent law, public health policy, and global access, highlighting strategic considerations and broader implications for the life sciences IP community in the event of a future pandemic. Topics of discussion will include:

- Exploring key takeaways from the COVID-19 vaccine patent disputes to inform future IP management strategies in health emergencies and on vaccine innovation
  - » E.g., Moderna vs. Pfizer/BioNTech mRNA vaccine dispute, assessing their legal arguments, impact on the pharma industry, and implications for biotech patent law
- Scrutinizing the interplay between public health policies, emergency use authorizations, and patent rights during pandemics and debating the ethical and legal challenges of balancing access with protection of innovation through patents
- Distilling the Commission's new mechanism for granting EU-wide compulsory licenses under patent rights without the consent of the patent holder in response to EU emergencies or crises
- Assessing the impact of voluntary patent pledges, such as AstraZeneca's non-profit vaccine pledge, on IP management in health crises

James Horgan
Chief IP Counsel, International Litigation and Policy
Merck Sharp & Dohme (UK)

Adam Mossoff
Professor of Law
Antonin Scalia Law School, George Mason University

MODERATED BY
Nina Bayerl
Partner
Freshields

16h00 AI in Drug and Therapeutic Discovery: Navigating Patent Challenges and New Regulatory Landscapes

The landscape for patenting AI technologies in drug discovery is being shaped by new regulations and case law, impacting how companies approach IP protection and litigation. This session will detail the evolving challenges and opportunities in patenting AI-assisted drug discovery innovations, considering recent legal and regulatory developments in Europe and the U.S. Points of discussion will include:

- Exploring the impact of the European Union's AI Act, the first comprehensive AI law, on AI in drug discovery
- Examining the increasing trend of patent filings related to AI and machine learning in drug discovery
- Developing strategies for patenting AI innovations, including the challenges of meeting patentability criteria like novelty and non-obviousness
- Analyzing the importance of data exclusivity in AI-driven drug discovery, focusing on strategies for protecting proprietary data and the implications for patent enforcement
- Addressing the challenges of managing IP for AI-assisted drug discovery in a global context, taking into account different regulatory environments and the need for harmonized strategies

Richie Paul, Ph.D.
VP & Head of IP
Alkermes Pharma Ireland Limited

Daniel G. Rudoy, PhD
Shareholder | Executive Committee Member
Wolf, Greenfield & Sacks, P.C.

MODERATED BY:
Camille Terfve
Partner
Mewburn Ellis

17h00 Conference Concludes

Media Partners

Upcoming Events Driving Innovation and IP Strategy Across the Life Sciences Landscape

March 11–12 • NH Carrefour de L'Europe, Brussels

March 19–20 • Seaport Hotel, Boston, MA



March 25–26 • NH Collection Brussels Grand Sablon, Brussels

April 29–30 • The Altman Building, New York, NY

May 19–20 • New York Bar Association, New York, NY

June 2–3 • Metcalf Trustee Center, Boston University, Boston, MA

June 4 • Metcalf Trustee Center, Boston University, Boston, MA

July 30–31 • Boston University, George Sherman Union Building, MA

REGISTER NOW C5-Online.com/**PPLitigation** • +44 20 4532 2313

Part of C5 Group's
LIFE SCIENCES GLOBAL SERIES

Venue & Hotel

Radisson Blu Hotel, Amsterdam City Centre
Rusland 17, 1012 CK Amsterdam, Netherlands

ACCOMMODATIONS

C5 Communications Ltd. is pleased to offer our delegates a limited number of hotel rooms at a negotiated rate. To take advantage of these rates, please contact the hotel directly and quote "**C5 Communications**".

Reservations: +31 20 623 1231

How to reserve a hotel room with a Promotional code

1. Go to **https://www.radissonhotels.com/en-us/hotels/radisson-blu-amsterdam**
2. Enter the dates of the stay (20 – 20/05, 2025) and fill in the required number of rooms and guests
3. Select the number of adults
4. Click on "Special rates" (a drop down menu will appear)
5. Select "Promotional Code"
6. Fill out the appearing empty box with "**2025C5**"
7. Click on "Book"
8. Select the applicable and available room and follow the further booking procedure

Please note that the guest room block cut-off date is **18 April 2025**.
After that date OR when the room block fills, guestroom availability and rate can no longer be guaranteed.

Book with Confidence!

Register and pay to lock in your early rate and be eligible for a full refund until 14 May 2025.
If you are unable to attend for any reason, you will have the following options:

- A full credit note for you, or a colleague to attend another event.
- A full refund.

All cancellations and changes must be submitted to Registration@C5-Online.com by 14 May 2025.

3 Ways to Register

ONLINE:
C5-Online.com/PPLitigation

EMAIL:
Registration@C5-Online.com

PHONE:
+44 20 4532 2313

SAVE €200

PRICING	Register & Pay by 25 April 2025	Register & Pay after 25 April 2025
Please add 21% Dutch VAT to all orders if not established in the Netherlands and not providing a Dutch VAT number		
Standard	€2399	€2599
In-House Counsel†	€1399	€1599

†C5 reserves the right to review eligibility for the In-House Counsel special rate.

All program participants will receive an online link to access the conference materials as part of their registration fee. Additional copies of the Conference Materials available for $199 per copy.

To update your contact information and preferences, please visit https://www.C5-Online.com/preference-center/. Terms & conditions and refund/cancellation policies can be found at C5-Online.com/company/faq/

REGISTRATION CODE:
B00-630-630L25.WEB

CONFERENCE CODE:
630L25-AMS

Bringing a Team?*	
1–3	No Discount
4–8	10% Conference Discount
9–12	15% Conference Discount
12+	Call +44 20 4532 2313

**Team/group registrations must be from the same organization/firm and register together in one transaction.*